In vitro studies of berberine metabolism and its effect of enzyme induction on HepG2 cells

Journal of Ethnopharmacology

Volumn 158, Issue PART A, 2014, Pages 388-396

  Cui, Han Ming ^a   Zhang, Qiu Yan ^a   Wang, Jia Long ^a   Chen, Jian Long ^a   Zhang, Yu Ling ^a   Tong, Xiao Lin ^a  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

Author keywords

Berberine; CYP enzyme; Drug metabolism; Drug drug interaction; HepG2 cell; Metabolic enzyme induction

Indexed keywords

BERBERINE; CHLORZOXAZONE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C; CYTOCHROME P450 2C9; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; MIDAZOLAM; PHENACETIN; TOLBUTAMIDE; CYTOCHROME P450 3A; MESSENGER RNA; PRIMER DNA;

ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DRUG METABOLISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME METABOLISM; GENE EXPRESSION; GENETIC TRANSCRIPTION; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CLEARANCE; METABOLIC RATE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; WESTERN BLOTTING; BIOSYNTHESIS; DRUG EFFECTS; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; VALIDATION STUDY;

BASE SEQUENCE; BERBERINE; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP3A; DNA PRIMERS; ENZYME INDUCTION; HEP G2 CELLS; HUMANS; IN VITRO TECHNIQUES; POLYMERASE CHAIN REACTION; RNA, MESSENGER; TANDEM MASS SPECTROMETRY;

EID: 84911494444     PISSN: 03788741     EISSN: 18727573     Source Type: Journal    
DOI: 10.1016/j.jep.2014.10.018     Document Type: Article

References (84)

1. S. Bandyopadhyay, P.H. Patra, A. Mahanti, D.K. Mondal, P. Dandapat, S. Bandyopadhyay, I. Samanta, C. Lodh, A.K. Bera, D. Bhattacharyya, M. Sarkar, and K.K. Baruah Potential antibacterial activity of berberine against multi drug resistant enterovirulent Escherichia coli isolated from yaks (Poephagus grunniens) with haemorrhagic diarrhea Asian Pacific Journal of Tropical Medicine 6 2013 315 319
2. K. Bhadra, and G.S. Kumar Interaction of berberine, palmatine, coralyne, and sanguinarine to quadruplex DNA: a comparative spectroscopic and calorimetric study Biochimica et Biophysica Acta-General Subjects 810 2011 485 496
3. G.E. Blakey, J.A. Lockton, J. Perrett, P. Norwood, M. Russell, Z. Aherne, and J. Plume Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1 British Journal of Clinical Pharmacology 57 2004 162 169
4. M.I. Borges-Walmsley, K.S. Mckeegan, and A.R. Walmsley Structure and function of efflux pumps that confer resistance to drugs Biochemical Journal 376 2003 313 338
5. E. Chan, M. Tan, J.N. Xin, S. Sudarsanam, and D.E. Johnson Interactions between traditional Chinese medicines and Western therapeutics Current Opinion in Drug Discovery & Development 13 2010 50 65
6. P. Chatterjee, and M.R. Franklin Human cytochrome P450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components Drug metabolism and disposition 31 2003 1391 1397
7. W. Chatuphonprasert, N. Nemoto, T. Sakuma, and K. Jarukamjorn Modulations of cytochrome P450 expression in diabetic mice by berberine Chemico-Biological Interactions 196 2012 23 29
8. G. Chen, F. Lu, L.J. Xu, H. Dong, P. Yi, F. Wang, Z.Y. Huang, and X. Zou The anti-diabetic effects and pharmacokinetic profiles of berberine in mice treated with Jiao-Tai-Wan and its compatibility Phytomedicine 20 2013 780 786
9. J.L. Chen, Y.L. Zhang, Y. Dong, J.Y. Gong, and H.M. Cui CYP450 enzyme inhibition of berberine in pooled human liver microsomes by cocktail probe drugs China Journal of Chinese Materia Medica 38 2013 2009 2014
10. U.K. Choi, M.H. Kim, and N.H. Lee Optimization of antibacterial activity by Gold-Thread (Coptidis Rhizoma Franch) against Streptococcus mutans using evolutionary operation-factorial design technique Journal of Microbiology Biotechnology 17 2007 1880 1884
11. V. Chu, H.J. Einolf, R. Evers, G. Kumar, D. Moore, S. Ripp, J. Silva, V. Sinha, M. Sinz, and A. Skerjanec In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of America perspective Drug Metabolism and Disposition 37 2009 1339 1354
12. A.F. Cicero, and S. Ertek Metabolic and cardiovascular effects of berberine: from preclinical evidences to clinical trial results Clinical Lipidology 4 2009 553 563
13. A. Cornish-Bowden Fundamentals of Enzyme Kinetics 2004 Portland Press London
14. G. Derosa, P. Maffioli, and A.F. Cicero Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials Expert Opinion on Biological Therapy 12 2012 1113 1124
15. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers, U.S. FDA, 2011. 〈http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm〉
16. T. Efferth, Z.P. Chen, B. Kaina, and G. Wang Molecular determinants of response of tumor cells to berberine Cancer Genomics & Proteomics 2 2005 115 124
17. J.J. Eloranta, P.J. Meier, and G.A. Kullak-Ublick Coordinate transcriptional regulation of transport and metabolism Methods in Enzymology 400 2005 511 530
18. R. Enk, R. Ehehalt, J.E. Graham, A. Bierhaus, A. Remppis, and H.J. Greten Differential effect of Rhizoma coptidis and its main alkaloid compound berberine on TNF-α induced NF-kB translocation in human keratinocytes Journal of Ethnopharmacology 109 2007 170 175
19. C. Fahrmayr, J. König, D. Auge, M. Mieth, and M.F. Fromm Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1- UGT1A1-MRP2 cells British Journal of Pharmacology 165 2012 1836 1847
20. R. Gebhardt, J.G. Hengstler, and D. Muller New hepatocyte in vitro systems for drug metabolism: metabolic capacity and recommendations for application in basic research and drug development, standard operation procedures Drug Metabolism Review 35 2003 145 213
21. M.J. Gomez-Lechon, M.T. Donato, J.V. Castell, and R. Jover Human hepatocytes in primary culture: the choice to investigate drug metabolism in man Current Drug Metabolism 5 2004 443 462
22. L. Grycová, J. Dostál, and R. Marek Quaternary protoberberine alkaloids Phytochemistry 68 2007 150 175
23. Guidance for Industry: Bioanalytical Method Validation, 2001. 〈http://www.fda.gov/downloads/Drugs/Guidances /ucm070107.pdf〉
24. Guidance for Industry: Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations, 2012. 〈http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf〉
25. Guidance for Industry: Drug Metabolism/Drug Interaction Studies in the Drug Development Process: Studies In Vitro, 1997. 〈http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/UCM142439.pdf〉
26. M. Gulfraz, S. Mehmood, A. Ahmad, N. Fatima, Z. Praveen, and E.M. Williamson Comparison of the antidiabetic activity of Berberis lyceum root extract and berberine in alloxan-induced diabetic rats Phytotherapy Research 22 2008 1208 1212
27. Y. Guo, Y. Chen, Z.R. Tan, C.D. Klaassen, and H.H. Zhou Repeated administration of berberine inhibits cytochromes P450 in humans European Journal of Clinical Pharmacology 68 2012 213 217
28. Y Guo, F Li, X.C. Ma, X.G. Cheng, H.H Zhou, and C,D. Klaassen CYP2D plays a major role in berberine metabolism in liver of mice and humans Xenobiotica 41 2011 996 1005
29. Y. Guo, C. Pope, X.G. Cheng, H.H. Zhou, and C.D Klaassen Dose-response of berberine on hepatic cytochromes P450 mRNA expression and activities in mice Journal of Ethnopharmacology 138 2011 111 118
30. B.J. Gurley, S.F. Gardner, M.A. Hubbard, D.K. Williams, W.B. Gentry, I.A. Khan, and A. Shah In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4 phenotypes Clinical Pharmacology & Therapeutics 77 2005 415 426
31. B.J. Gurley, A. Swain, G.W. Barone, D.K. Williams, P. Breen, C.R Yates, L.B. Stuart, M.A. Hubbard, Y.D. Tong, and S. Cheboyina Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans Drug Metabolism and Disposition 35 2007 240 245
32. B.J. Gurley, A. Swain, M.A. Hubbard, D.K. Williams, G. Barone, F. Hartsfield, Y.D. Tong, D.J. Carrier, S. Cheboyina, and S.K. Battu Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea Molecular Nutrition & Food Research 52 2008 755 763
33. Y.L. Han, H.L. Yu, D. Li, X.L. Meng, Z.Y. Zhou, Q. Yu, X.Y. Zhang, F.J. Wang, and C. Guo In vitro inhibition of Huanglian [Rhizoma coptidis (L.)] and its six active alkaloids on six cytochrome P450 isoforms in human liver microsomes Phytotherapy Research 25 2011 1660 1665
34. A.J. Harris, S.L. Dial, and D.A. Casciano Comparison of basal gene expression profiles and effects of hepatocarcinogens on gene expression in cultured primary human hepatocytes and HepG2 cells Mutation Research 549 2004 79 99
35. R. Hermann, and O.V. Richter Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions Planta Medica 78 2012 1458 1477
36. J.M. Hutzler, and T.S. Tracy Atypical kinetic profiles in drug metabolism reaction Drug Metabolism and Disposition 30 2002 355 362
37. M.M. Islam, P. Pandya, S.R. Chowdhury, S. Kumar, and G.S. Kumar Binding of DNA-binding alkaloids berberine and palmatine to tRNA and comparison to ethidium: spectroscopic and molecular modeling studies Journal of Molecular Structure 891 2008 498 507
38. H. Iwata, Y. Tezuka, T. Usia, S. Kadota, A. Hiratsuka, and T. Watabe Inhibition of human liver microsomal CYP3A4 and CYP2D6 by extracts from 78 herbal medicines Journal of Traditional Medicines 21 2004 42 50
39. C.T. Keith, A.A. Borisy, and B.R. Stockwell Multicomponent therapeutics for networked systems Nature Reviews Drug Discovery 4 2005 1 7
40. H.Y. Kim, H.S. Shin, H. Park, Y.C. Kim, Y.G. Yun, S. Park, H.J. Shin, and K. Kim In vitro inhibition of coronavirus replications by the traditionally used medicinal herbal extracts, Cimicifuga rhizoma, Meliae cortex, Coptidis rhizoma, and Phellodendron cortex Journal of Clinical Virology 41 2008 122 128
41. W.J. Kong, J. Wei, Z.Y. Zuo, Y.M. Wang, D.Q. Song, X.F. You, L.X. Zhao, H.N. Pan, and J.D. Jiang Combination of simvastatin with berberine improves the lipid-lowering efficacy Metabolism 57 2008 1029 1037
42. A. Lahoz, M.R. Vilà, M. Fabre, J.M. Miquel, M. Rivas, and J. Maines An in vitro tool to assess cytochrome P450 drug biotransformation-dependent cytotoxicity in engineered HepG2 cells generated by using adenoviral vectors Toxicology In Vitro 27 2013 1410 1415
43. H.L. Lin, T.Y. Liu, W.Y. Lui, and C.W. Chi Up-regulation of multidrug resistance transporter expression by berberine in human and murine hepatoma cells Cancer 85 1999 1937 1942
44. Y. Li, G. Ren, Y.X. Wang, W.J. Kong, P. Yang, Y.M. Wang, Y.H. Li, H. Yi, Z.R. Li, D.Q. Song, and J.D. Jiang Bioactivities of berberine metabolites after transformation through CYP450 isoenzymes Journal of Translational Medicine 9 2011 1 10
45. Y.T. Liu, H.P. Hao, H.G. Xie, L. Lai, Q. Wang, C.X Liu, and G.J. Wang Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats Drug metabolism and disposition 38 2010 1779 1784
46. Y.T. Liu, H.P. Hao, H.G. Xie, H. Lv, C.X. Liu, and G.J. Wang Oxidative demethylenation and subsequent glucuronidation are the major metabolic pathways of berberine in rats Journal of Pharmaceutical Sciences 98 2009 4391 4401
47. J.J. Lu, W. Pan, Y.J. Hu, and Y.T. Wang Multi-target drugs: the trend of drug research and development PLoS One 7 2012 1 6
48. G. Luo, M. Cunningham, S. Kim, T. Burn, J. Lin, and M. Sinz CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes Drug Metabolism Disposition 30 2002 795 804
49. R. Musumeci, A. Speciale, R. Costanzo, A. Annino, S. Ragusa, A. Rapisarda, M.S. Pappalardo, and L Iauk Berberis aetnensis C. Presl. extracts: antimicrobial properties and interaction with ciprofloxacin International Journal of Antimicrobial Agents 22 2003 48 53
50. R. Nowack Cytochrome P450 enzyme, and transport protein mediated herb-drug interactions in renal transplant patients: grapefruit juice, St John's Wort-and beyond! Nephrology 13 2008 337 347
51. PR. Ortiz de Montellano Cytochrome P450: Structure, Mechanism, and Biochemistry, third ed 2005 Kluwer Academic/Pleum Publishers New York 183-245
52. G.Y. Pan, G.J. Wang, X.D. Liu, J.P. Fawcett, and Y.Y. Xie The involvement of P-glycoprotein in berberine absorption Pharmacology & Toxicology 91 2002 193 197
53. Y. Qin, J.Y. Pang, W.H. Chen, Z.W. Cai, and Z.H. Jiang Synthesis, DNA-binding affinities, and binding mode of berberine dimmers Bioorganic & Medicinal Chemistry 14 2006 25 32
54. H. Quan, Y.Y. Cao, Z. Xu, J.X. Zhao, P.H. Gao, X.F. Qin, and Y.Y. Jiang Potent in vitro synergism of fluconazole and berberine chloride against clinical isolates of Candida albicans resistant to fluconazole Antimicrobial Agents and Chemotherapy 50 2006 1096 1099
55. J.K. Richard A U.S. perspective on the adverse reactions from traditional Chinese medicines Journal of Chinese Medical Association 67 2004 109 116
56. S. Seeland, M. Torok, H. Kettiger, A. Treiber, M. Hafner, and J. Huwyler A cell-based, multiparametric sensor approach characterises drug-induced cytotoxicity in human liver HepG2 cells Toxicology In Vitro 27 2013 1109 1120
57. T.L. Serafim, P.J. Oliveira, V.A. Sardao, E. Perkins, D. Parke, and J. Holy Different concentrations of berberine result in distinct cellular localization patterns and cell cycle effects in a melanoma cell line Cancer Chemotherapy Pharmacology 61 2008 1007 1018
58. R. Shi, H. Zhou, Z.M. Liu, Y.M. Ma, T.M Wang, Y.Y. Liu, and C.H. Wang Influence of coptis Chinensis on pharmacokinetics of flavonoids after oral administration of radix Scutellariae in rats Biopharmaceutics & Drug Disposition 30 2009 398 410
59. J.S. Sorensen, and M.D. Dearing Efflux transporters as a novel herbivore countermechanism to plant chemical defenses Journal of Chemical Ecology 32 2006 1181 1196
60. J. Tang, Y.B. Feng, S. Tsao, N. Wang, R. Curtain, and Y.W Wang Berberine and Coptidis rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations Journal of Ethnopharmacology 126 2009 5 17
61. L.K. Teh, and L. Bertilsson Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance Drug Metabolism Pharmacokinetics 27 2012 55 67
62. P. Timmerman, M. Anders Kall, B. Gordon, S. Laakso, A. Freisleben, and R. Hucker Best practices in a tiered approach to metabolite quantification: views and recommendations of the European Bioanalysis Forum Bioanalysis 2 2010 1185 1194
63. N.N. Tong, J. Zhang, Y.R. Chen, Z.B. Li, Y.H. Luo, H. Zuo, and X.Y. Zhao Berberine sensitizes mutliple human cancer cells to the anticancer effects of doxorubicin in vitro Oncology letters 3 2012 1263 1267
64. P.L. Tsai, and T.H. Tsai Hepatobiliary excretion of berberine Drug Metabolism and Disposition 32 2004 405 412
65. P.L. Tsai, and T.H. Tsai Measurement of unbound pravastatin in rat blood and bile on the perspective of hepatobiliary excretion and its interaction with cyclosporin A and berberine Analytica Chimica Acta 548 2005 33 40
66. N. Turner, J.Y. Li, A. Gosby, W.C. Sabrina, Z. Cheng, H. Miyoshi, M.M. Taketo, G.J. Cooney, E.W. Kraegen, D.E. James, L.H. Hu, J. Li, and J.M. Ye Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I Diabetes 57 2008 1414 1418
67. R. Vrzal, A. Zdařilová, J. Ulrichova, L. Bláha, J.P. Giesy, and Z. Dvořák Activation of the aryl hydrocarbon receptor by berberine in HepG2 and H4IIE cells: biphasic effect on CYP1A1 Biochemical Pharmacology 70 2005 925 936
68. D.W. Wang, Z.Q. Liu, M.Q. Guo, and S.Y. Liu Structural elucidation and identification of alkaloids in Rhizoma Coptidis by electrospray ionization tandem mass spectrometry Journal of Mass Spectrometry 39 2004 1356 1365
69. Y.G. Wang, M.M. Kheir, Y.S. Chai, J. Hu, D.M. Xing, F. Lei, and L.J. Du Comprehensive study in the inhibitory effect of berberine on gene transcription, including TATA box PLoS One 6 2011 1 11
70. Z. Wang, H. Hu, F. Chen, K. Lan, and A. Wang Reduced system exposures of total rhein and baicalin after combinatory oral administration of rhein, baicalin and berberine to beagle dogs and rats Journal of Ethnopharmacology 145 2013 442 449
71. W.M. Westerink, and W.G. Schoonen Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells Toxicology In Vitro 21 2007 1581 1591
72. J.J. Wu, C.Z. Ai, Y. Liu, Y.Y. Zhang, M. Jiang, X.R. Fan, A.P. Lv, and L. Yang Interactions between phytochemicals from traditional Chinese medicines and human cytochrome P450 enzymes Current Drug Metabolism 13 2012 599 614
73. X.C. Wu, Q. Li, H.W. Xin, A.R. Yu, and M.Y. Zhong Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study European Journal of Clinical Pharmacology 61 2005 567 572
74. A.L. Xia, H.L. Wu, S.F. Li, S.H. Zhu, Y. Zhang, Q.J. Han, and R.Q. Yu Study of the interactions of berberine and daunorubicin with DNA using alternating penalty trilinear decomposition algorithm combined with excitation-emission matrix fluorescence data Talanta 73 2007 606 612
75. H.W. Xin, X.C. Wu, Q. Li, A.R. Yu, M.Y. Zhong, and Y.Y. Liu The effects of berberine on the pharmacokinetics of ciclosporin A in healthy volunteers Methods and Findings in Experimental and Clinical Pharmacology 28 2006 25 29
76. X.S. Ye, Y.B Feng, Y. Tong, KM Ng, S. Tsao, G.K. Lau, C. Sze, Y.B. Zhang, J. Tang, J. Shen, and S. Kobayashi Hepatoprotective effects of Coptidis rhizoma aqueous extract on carbon tetrachloride-induced acute liver hepatotoxicity in rats Journal of Ethnopharmacology 124 2009 130 136
77. K.T. Yoshida, K. Maeda, and Y.C. Sugiyama Hepatic and intestinal drug transporters: prediction of pharmacokinetic effects caused by drug-drug interactions and genetic polymorphisms Annual Review of Pharmacology and Toxicology 53 2013 581 612
78. S. Yoshitomi, K. Ikemoto, J. Takahashi, H. Miki, M. Namba, and S. Asahi Establishment of the transformants expressing human cytochrome P450 subtypes in HepG2, and their applications on drug metabolism and toxicology Toxicology In Vitro 15 2001 245 256
79. R. Yuan, S. Madani, X.X. Wei, K. Reynolds, and S.M. Huang Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions Drug Metabolism and Disposition. 30 2002 1311 1319
80. X.F. Zhang, F.R. Qiu, J. Jiang, C.L. Gao, and Y.Z. Tan Intestinal absorption mechanisms of berberine, palmatine, jateorhizine, and coptisine: involvement of P-glycoprotein General Xenobiochemistry 41 2011 290 296
81. Y. Zhao, B.H. Hellum, A. Liang, and O.G. Nilsen The in vitro inhibition of human CYP1A2, CYP2D6 and CYP3A4 by tetrahydropalmatine, neferine and berberine Phytotherapy Research 26 2012 277 283
82. W.B. Zha, G.J. Wang, W.R. Xu, X.Y. Liu, Y. Wang, B.S. Zha, J. Shi, Q.J. Zhao, P.M. Gerk, E. Studer, P.B. Hylemon, W.M. Pandak, and H.P. Zhou Inhibition of P-glycoprotein by HIV protease inhibitors increases intracellular accumulation of berberine in murine and human macrophages PLoS One 8 2013 1 9
83. Y.M. Zhou, P. He, A.M. Liu, L.X. Zhang, Y.D. Liu, and R.K. Dai Drug-drug interactions between ketoconazole and berberine in rats: pharmacokinetic effects benefit pharmacodynamic synergism Phytotherapy Research 26 2011 772 777
84. F. Zuo, N. Nakamura, T. Akao, and M. Hattori Pharmacokinetics of berberine and its main metabolites in conventional and pseudo germ-free rats determined by liquid chromatography/ion trap mass spectrometry Current Drug Metabolism 34 2006 2064 2072